Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. She is a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program, and the Institute for Stem Cell Biology and Regenerative Medicine. She has attended on the BMT clinical service since 1997. Dr. Shizuru’s research focuses on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic bone marrow cells and the way in which bone marrow grafts modify immune responses. This research complements her group’s interest in clinical bone marrow transplantation, and aspects of these studies are aimed at solving some of the major problems of bone marrow transplantation, which include graft-vs-host disease and bone marrow engraftment failure. Conventional bone marrow transplantation involves the transfer of heterogeneous populations of cells composed of rare hematopoietic stem cells and differentiated blood cell types. To study these issues, her lab’s approach has been to transplant phenotypically purified cells under defined conditions.

Dr. Weiss is the Ephraim P. Engleman Distinguished Professor of Rheumatology in the Department of Medicine at the University of California, San Francisco, where he has been on the faculty since 1985. He served as Division Chief of Rheumatology at UCSF from 1988-2011. He has been an Investigator of the Howard Hughes Medical Institute since 1985.

Dr. Weiss is a leader in the field of signal transduction in the immune system, focusing on the roles of tyrosine kinases and phosphatases in regulating lymphocyte activation. He is interested in how abnormalities in tyrosine phosphorylation pathways can lead to immunologically-mediated diseases. He has coauthored more than 250 peer-reviewed original research publications and more than 80 reviews. Dr. Weiss received the William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute, the Lee C. Howley Prize from the Arthritis Foundation, the Distinguished Investigator Award from the American College of Rheumatology, and the Meritorious Career Award from the American Association of Immunologists (AAI) and the Huang Foundation. He is also a recipient of the Lifetime Achievement Award from the AAI. He is a member of the National Academy of Sciences, National Academy of Medicine, American Academy of Arts and Sciences, and the American Academy of Microbiology.

Dr. Appelbaum studies the biology and treatment of leukemias, lymphomas and other blood cancers and sees patients with these disorders. He has made numerous landmark contributions to his field. Notably, he helped develop the renowned program in blood stem cell transplantation at the Fred Hutchinson Cancer Research Center, where he participated in its pioneering work to develop targeted antibody-based cancer therapies. Today, Dr. Appelbaum leads the Adult Leukemia Research Center and the Hematologic Malignancy Program of the Fred Hutchinson/University of Washington Cancer Consortium. These efforts are aimed at enhancing the understanding of these diseases and improving treatments such as blood stem cell transplantation. As Fred Hutch Deputy Director, Dr. Appelbaum leads the implementation of key scientific strategies and partnerships. He also helps to ensure that Fred Hutch advances are shared with the wider community.

Jeffrey V. Ravetch, M.D., Ph.D. is currently the Theresa and Eugene Lang Professor at the
Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and
Immunology.

Dr. Ravetch, a native of New York City, earned degrees from Yale University, Cornell Medical
College and The Rockefeller University and pursued postdoctoral studies at the NIH. From 1982
to 1996 Dr. Ravetch was a member of the faculty of Memorial Sloan-Kettering Cancer Center
and Cornell Medical College. His laboratory has focused on the Fc domain of antibodies and
their receptors, establishing their structural and functional diversity and the pre-eminence of FcR
pathways in host defense, inflammation and tolerance. His work has been widely extended into
clinical applications for the treatment of neoplastic, inflammatory and infectious diseases.

Dr. Ravetch has received numerous awards including the William B. Coley Award (2007),
Sanofi-Pasteur Award (2012), Gairdner International Prize (2012), Wolf Prize in Medicine
(2015), Ross Prize in Molecular Medicine (2017) and the Robert Koch award (2018). He is a
member of National Academy of Sciences (2006), the National Academy of Medicine (2007), a
Fellow of the American Academy of Arts and Sciences (2008) and a Fellow of the American
Association for the Advancement of Science (2009).

Ravetch has contributed extensively to the scientific community by serving as a member of the
Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Medical
Research, the Damon Runyon Foundation, the medical advisory board of Gairdner Foundation,
the Sanofi-Pasteur Award Jury and the L’Oreal Women in Science Jury. He has been active in
biotechnology for the last two decades, and currently serves as a consultant or member of the
Scientific Advisory Boards of Harpoon, Kleo, Momenta, Palleon, Portola and Xencor.

Dr. Kunkel has more than 20 years of experience in oncology and immunology drug development and commercialization. From October 2013 to October 2014, she was the acting Chief Medical Officer of Loxo Oncology, Inc. Prior to that, she was Chief Medical Officer of Pharmacyclics LLC, which was acquired by AbbVie, and Chief Medical Officer of Proteolix, Inc., which was acquired by Onyx Pharmaceuticals. Prior to those positions, she held various senior clinical roles at Baxter Healthcare, Chiron Corp, Genentech, Inc. and Xencor, Inc. Additionally, as a clinical drug development specialist, Dr. Kunkel has advised multiple clients including Atreca, Enliven Therapeutics, Elevation Oncopeptides, Oryzon Genomics and Rain Therapeutics. Prior to joining the biotechnology industry, Dr. Kunkel spent 10 years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at the University of California, Los Angeles. She currently serves on the board of directors of Curis Inc, Maverick Therapeutics, Oric Pharma and Nurix Therapeutics and previously served on the board of directors of Loxo Oncology, Amphivena, Harpoon Therapeutics and Tocagen. Dr. Kunkel received a medical degree from the University of Southern California and a bachelor’s degree in biology from the University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.

Dr. Malech is currently Chief of the Genetic Immunotherapy Section (GIS), and Deputy Chief of the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The mission of GIS is the development of gene therapy and hematopoietic stem cell transplantation approaches to the treatment of a variety of inherited primary immune deficiencies. Associated with that mission is the diagnosis and treatment of the infections, inflammation, autoimmunity, pulmonary dysfunction, and growth failure that may complicate management of a number of primary immune deficiencies. He has overseen clinical trials of gene therapies that use ex vivo transduction of autologous hematopoietic stem cells, as well as studies of allogeneic HSC transplantation for rare diseases.

Dr. Malech received his medical degree from Yale University in New Haven, Connecticut. He completed clinical residency training at the University of Pennsylvania in Philadelphia, followed by basic research postdoctoral fellowship training at the National Institutes of Health (NIH) in Bethesda, Maryland. After then completing clinical fellowship training in infectious diseases at Yale University, he remained at Yale as assistant and then associate professor. In 1986, he returned to NIH as a senior investigator in NIAID.

Dr. Stephen Galli is a globally recognized expert on mast cells and basophils, with a distinguished record as a researcher, educator, and administrative leader. During his tenure as the Chair of the Department of Pathology at Stanford University, spanning from 1999 to 2016, Dr. Galli mentored numerous individuals in research and clinical pathology, while also establishing a career development program for residents across all departments. Prior to joining Stanford, Dr. Galli was a professor of Pathology at Harvard Medical School and served as Director of the Division of Experimental Pathology at Beth Israel Deaconess Medical Center.

Dr. Galli’s research is centered around the roles played by mast cells and basophils in immunological and inflammatory responses, with particular emphasis on their involvement in anaphylaxis, food allergies, and asthma. He has also made significant contributions towards elucidating the function of mast cells in promoting both innate and acquired, IgE-enhanced, host defense against venoms and certain bacteria. Furthermore, his research has led to the discovery that mast cells play a crucial role in maintaining homeostasis and ensuring survival.

Dr. Galli earned his BA in Biology from Harvard College, followed by a BMS from Dartmouth Medical School and an MD from Harvard Medical School.